104 related articles for article (PubMed ID: 10970702)
1. Sample sizes for cancer trials where Health Related Quality of Life is the primary outcome.
Julious SA; Campbell MJ; Walker SJ; George SL; Machin D
Br J Cancer; 2000 Oct; 83(7):959-63. PubMed ID: 10970702
[TBL] [Abstract][Full Text] [Related]
2. The use of bootstrap methods for estimating sample size and analysing health-related quality of life outcomes.
Walters SJ; Campbell MJ
Stat Med; 2005 Apr; 24(7):1075-102. PubMed ID: 15570625
[TBL] [Abstract][Full Text] [Related]
3. Sample size and power estimation for studies with health related quality of life outcomes: a comparison of four methods using the SF-36.
Walters SJ
Health Qual Life Outcomes; 2004 May; 2():26. PubMed ID: 15161494
[TBL] [Abstract][Full Text] [Related]
4. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
[TBL] [Abstract][Full Text] [Related]
5. Consultants' forum: should post hoc sample size calculations be done?
Walters SJ
Pharm Stat; 2009; 8(2):163-9. PubMed ID: 18416448
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian analysis of institutional effects in a multicenter cancer clinical trial.
Gray RJ
Biometrics; 1994 Mar; 50(1):244-53. PubMed ID: 8086608
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer.
Fallowfield LJ; Harper P
Lung Cancer; 2005 Jun; 48(3):365-77. PubMed ID: 15893006
[TBL] [Abstract][Full Text] [Related]
8. Diseases desperate grown.
Bunn PA
J Natl Cancer Inst; 2008 Apr; 100(8):520-1. PubMed ID: 18398099
[No Abstract] [Full Text] [Related]
9. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
10. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK;
J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033
[TBL] [Abstract][Full Text] [Related]
11. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer.
Richardson LC; Wang W; Hartzema AG; Wagner S
Breast J; 2007; 13(6):581-7. PubMed ID: 17983400
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
13. Etoposide (VP-16) containing combination chemotherapy for treatment of patients with small cell lung cancer.
Behera D; Jindal SK; Sharma SC
Indian J Chest Dis Allied Sci; 1995; 37(1):15-9. PubMed ID: 16892733
[TBL] [Abstract][Full Text] [Related]
14. Surgery for cure of small cell bronchial carcinoma (SCLC) at early stages and postoperative combined modality treatment.
Karrer K; Denck H; Karnicka-Mlodkowska H; Drings P; Erzen J; Salzer GM;
J Chemother; 1989 Jul; 1(4 Suppl):1207-8. PubMed ID: 16312836
[No Abstract] [Full Text] [Related]
15. How many do I need? Basic principles of sample size estimation.
Devane D; Begley CM; Clarke M
J Adv Nurs; 2004 Aug; 47(3):297-302. PubMed ID: 15238124
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
[TBL] [Abstract][Full Text] [Related]
18. [Maintenance chemotherapy for small-cell lung cancer. A new publication].
Margery J; Le Moulec S; Grassin F; Guigay J; Vaylet F; L'her P
Rev Pneumol Clin; 2003 Jun; 59(3):179-80. PubMed ID: 13130207
[No Abstract] [Full Text] [Related]
19. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
Sullivan LM; D'Agostino RB
Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
[TBL] [Abstract][Full Text] [Related]
20. [Early irradiation with radiochemotherapy for limited-stage small cell lung cancer is superior to late irradiation].
Fietkau R; Sauer R
Strahlenther Onkol; 2002 Nov; 178(11):585-8. PubMed ID: 12518770
[No Abstract] [Full Text] [Related]
[Next] [New Search]
